Review in translational hematology Myeloma bone disease and proteasome inhibition therapies
نویسندگان
چکیده
1Department of Hematology and Medical Research, 251 General Airforce Hospital, Athens, Greece; 2Department of Hematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom; 3Department of Hematology and Oncology, Charité-Universitaetsmedizin Berlin, Berlin, Germany; 4Academic Unit of Bone Biology, Section of Musculoskeletal Science, University of Sheffield Medical School, Sheffield, United Kingdom; 5Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
منابع مشابه
Novel therapeutic targets in multiple myeloma.
Multiple myeloma (MM) is a disorder of clonal plasma cells that accumulate in the bone marrow and secrete a monoclonal protein detectable in the blood and/or urine. In the last decade, the outcome of patients with MM has markedly improved owing to the introduction of agents such proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide, lenalidomide) as induction, consolidation...
متن کاملReview in translational hematology Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone...
متن کاملNovel treatment regimens for Waldenström's macroglobulinemia.
Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by bone marrow infiltration by lymphoplasmacytic cells as defined by the current classification systems. According to its transition situation between mutated chronic lymphocytic leukemia and multiple myeloma, several new therapeutic alternatives have been proposed for this entity based on the experience with ...
متن کاملMultiple Myeloma: New Insights and Therapeutic Approaches.
This review discusses the evolution of novel diagnostic and treatment strategies for multiple myeloma based upon increased understanding of basic disease pathogenesis. Although myeloma has remained an incurable illness to date, these new developments will derive treatments to improve outcome and achieve eventual cure. In Section I, Dr. Kyle reviews the results of current therapy for multiple my...
متن کاملBortezomib: proteasome inhibition as an effective anticancer therapy.
VELCADER (bortezomib, Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ) is a first-in-class proteasome inhibitor developed specifically for use as an antineoplastic agent. Inhibition of the proteasome results in disruption of homeostatic mechanisms within the cell that can lead to cell death. Bortezomib's first ind...
متن کامل